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Toxicities and Early Outcomes in a Phase 1 Trial of Photodynamic Therapy For
Premalignant and Early Stage Head and Neck Tumors
Abstract

Objectives
Management of early superficial lesions in the head and neck remains complex. We performed a phase 1
trial for high-grade premalignant and early superficial lesions of the head and neck using photodynamic
therapy (PDT) with Levulan (ALA).

Materials and methods
Thirty-five subjects with high grade dysplasia, carcinoma in situ, or microinvasive (⩽1.5 mm depth)
squamous cell carcinoma were enrolled. Cohorts of 3–6 patients were given escalating intraoperative
light doses of 50–200 J/cm2 4–6 h after oral administration of 60 mg/kg ALA. Light at 629–635 nm was
delivered in a continuous (unfractionated) or fractionated (two-part) schema.

Results
PDT was delivered to 30/35 subjects, with 29 evaluable. There was one death possibly due to the
treatment. The regimen was otherwise tolerable, with a 52% rate of grade 3 mucositis which healed within
several weeks. Other toxicities were generally grade 1 or 2, including odynophagia (one grade 4), voice
alteration (one grade 3), and photosensitivity reactions. One patient developed grade 5 sepsis. With a
median follow-up of 42 months, 10 patients (34%) developed local recurrence; 4 of these received 50 J/
cm2 and two each received 100, 150, and 200 J/cm2. Ten (34%) patients developed recurrence adjacent
to the treated field. There was a 69% complete response rate at 3 months.

Conclusions
ALA-PDT is well tolerated. Maximum Tolerated Dose appears to be higher than the highest dose used in
this study. Longer followup is required to analyze effect of light dose on local recurrence. High marginal
recurrence rates suggest use of larger treatment fields.
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SUMMARY
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Objectives—Management of early superficial lesions in the head and neck remains complex.
We performed a phase 1 trial for high-grade premalignant and early superficial lesions of the head
and neck using photodynamic therapy (PDT) with Levulan (ALA).
Materials and methods—Thirty-five subjects with high grade dysplasia, carcinoma in situ,
or microinvasive (≤1.5 mm depth) squamous cell carcinoma were enrolled. Cohorts of 3–6 patients
were given escalating intraoperative light doses of 50–200 J/cm2 4–6 h after oral administration of
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60 mg/kg ALA. Light at 629–635 nm was delivered in a continuous (unfractionated) or
fractionated (two-part) schema.
Results—PDT was delivered to 30/35 subjects, with 29 evaluable. There was one death
possibly due to the treatment. The regimen was otherwise tolerable, with a 52% rate of grade 3
mucositis which healed within several weeks. Other toxicities were generally grade 1 or 2,
including odynophagia (one grade 4), voice alteration (one grade 3), and photosensitivity
reactions. One patient developed grade 5 sepsis. With a median follow-up of 42 months, 10
patients (34%) developed local recurrence; 4 of these received 50 J/cm2 and two each received
100, 150, and 200 J/cm2. Ten (34%) patients developed recurrence adjacent to the treated field.
There was a 69% complete response rate at 3 months.

Author Manuscript

Conclusions—ALA-PDT is well tolerated. Maximum Tolerated Dose appears to be higher
than the highest dose used in this study. Longer followup is required to analyze effect of light dose
on local recurrence. High marginal recurrence rates suggest use of larger treatment fields.
Keywords
Photodynamic therapy; Levulan; Head and neck cancer; Severe dysplasia; Carcinoma in situ;
ALA; PDT; Aminolevulinic acid; Protoporphyrin IX

Introduction

Author Manuscript

Photodynamic therapy (PDT) uses a photosensitizing agent and light to kill cells, involving
delivery of a photosensitizer or photosensitizer precursor followed by illumination at a
specific wavelength of light. The appeal of PDT in oncology has been that photosensitizers
such as Photofrin are retained in tumor tissues for longer periods compared to normal tissue.
The selectivity of photosensitizer for diseased tissue, as well as the ability to target the light
directly to diseased areas, has prompted interest in studying PDT as an organ-preserving
treatment for premalignant and malignant conditions. Clinical reports of PDT in the
treatment of malignancies include head and neck cancers [1], lung cancer [2,3],
mesothelioma [4], esophageal [5], brain [6], breast [7,8], bladder [9,10], and prostate cancers
[11].

Author Manuscript

Early superficial lesions in the oral cavity, larynx and pharynx are ideal PDT targets because
head and neck anatomy often offers direct access for the laser. Depth of penetration of the
laser light ranges from a few millimeters up to 20 mm depending on wavelength [12]. In a
report of his experience and literature review, Biel showed an 89% complete response rate in
patients with carcinoma in situ or early stage head and neck cancers treated with PDT and
Photofrin as photosensitizer [13]. Preclinical reports of Photofrin for head and neck cancer
have indicated possible benefit to two-part fractionated light delivery for tumor control [14].
PDT offers an attractive function-preserving alternative for patients in circumstances in
which surgical resection can be cosmetically and functionally debilitating.
Using Photofrin as photosensitizer in PDT is associated with an extended period of skin
sensitivity to light, lasting up to 6–8 weeks after drug administration, which is a deterrent for
ambulatory patients with early stage disease. One Photofrin alternative is 5-aminolevulinic
acid or ALA (Levulan®, DUSA Pharmaceuticals, Inc.), a natural precursor in the heme
Oral Oncol. Author manuscript; available in PMC 2017 April 01.
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biosynthetic pathway. ALA can be administered orally or topically, leading to the
endogenous production and accumulation of protoporphyrin IX (PpIX). PpIX is activated at
the same light wavelength as Photofrin (630 nm). Compared to the 6–8 week
photosensitivity with Photofrin, ALA-induced PpIX skin photosensitivity persists for 24–48
h after administration. ALA-mediated PDT has been used in animal studies for esophageal
[15], brain [16,17], and prostate cancer [18]. Orally administered ALA has been evaluated
clinically for high grade dysplasias and superficial cancers of the esophagus. A series of 5
patients of high-grade dysplasia with Barrett's esophagus were treated, without toxicities or
recurrences [19]. A series of 66 patients treated for high-grade intraepithelial neoplasia (31)
or early adenocarcinoma (35) demonstrated no major complications [20]. With median 37
month follow-up, disease free survival was 89% for high-grade intraepithelial neoplasia and
68% for mucosal cancer. Oral ALA has been reported for a total 14 patients with high-grade
dysplasia or microinvasive cancer of the head and neck. The above studies identify a dose of
60 mg/kg of oral ALA as safe in PDT for superficial epithelial lesions.
Due to the favorable absorption and clearance profiles of PpIX, we conducted a phase 1 trial
of orally administered ALA with escalating doses of PDT light for head and neck lesions.
The trial included patients with severe dysplasia, carcinoma in situ, or microinvasive
carcinoma of the head and neck, dividing treatment into fractionated and non-fractionated
cohorts. The primary purpose was assessing the safety and maximum tolerated PDT light
dose with orally administered ALA. Due to limited data on efficacy of ALA-mediated PDT
in this population, the secondary purpose was preliminarily assessing efficacy of ALA-PDT
in this population.

Methods
Author Manuscript

Patients were eligible if they had high-grade dysplasia, carcinoma in situ, or invasive
squamous cell carcinoma of the head and neck with depth of invasion ≤1.5 mm on surgical
biopsy or resection specimen as read by a dedicated pathologist. Patients with intact disease
or disease present at the resection margin were eligible, as long as the PDT procedure was
within 4 months of pathologic diagnosis. All subjects were treated in accordance with
protocols approved by the Institutional Review Board at the University of Pennsylvania.
Pretreatment evaluation included a complete history and physical examination, informed
consent, fiber-optic nasopharyngolaryngoscopy with digital photographs, routine laboratory
examination, and tissue diagnosis by the Department of Pathology.

Author Manuscript

ALA was administered as an oral dose of 60 mg/kg dissolved in 50 ml water 4–6 h prior to
light delivery. After oral administration of ALA, subjects remained in clinic with light
precautions. Vital signs were assessed before, immediately after ALA administration, every
15 min for the first two hours, and then hourly until the procedure.
Activating light generated using a Ceralas Series GaAlAs diode laser (Biolitec Inc., Vienna)
was applied 4–6 h after ALA administration. Study subjects were treated with a total fluence
of 50, 100, 150 and 200 J/cm2 using red light (629–635 nm). Light was delivered using
either a microlens (MedLight SA, Ecublens, Switzerland) or with a balloon diffusing fiber
(MedLight SA, Ecublens, Switzerland) depending on tumor location and shape. The
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microlens provided a collimated circular laser beam covering a superficial circular area in
accessible areas, and was used for most patients. For 9 patients, a microlens could not
adequately cover a cylindrically-shaped lesion. In these cases, a cylindrical diffusing fiber
with a chosen active length (2, 3, 4, 5 cm) was placed within a balloon catheter. The balloon
was inflated by saline to keep it in contact with the treated area. The light doses were
measured using an isotropic detector located in-situ at the treated surface for all patients. As
a result, the light dose was always correctly quantified regardless of applicator geometry. A
fluence rate of 100 mW/cm2 was delivered to the target, measured by a calibrated isotropic
detector positioned on the tissue surface. At each light dose, separate patient cohorts were
treated with continuous (unfractionated) or fractionated (two-part) illumination.
Fractionation involved delivery of 20% of fluence, a 90–180 s break, then resumption to full
fluence.

Author Manuscript

Almost all treatments were performed under general anesthesia. One patient with lower lip
pathology was treated as an outpatient under local anesthesia to the submental nerve. All
subjects were hospitalized overnight for observation. Biopsy specimens of diseased tissue
were collected before PDT in order to establish eligibility, as well as after PDT in order to
assess response (1 month in patients without a clinical response and at 3 months in all
patients).

Author Manuscript

Post-treatment, all patients were instructed to avoid sunlight for 3 days. Toxicity endpoints
were graded using the Cooperative Group Common Toxicity Criteria (CTCAE v.3.0).
Patients were followed week 1, week 2–3, day 30, day 90, every 3 months for 24 months,
and then annually. Dose-limiting toxicity (DLT) was defined by a grade 3 toxicity by 30
days after administration of PDT. Patients were taken off protocol if they underwent a
recurrence, but followed off-protocol for further progression.
For purposes of statistical analysis of treatment response, patients were divided into groups
receiving low (50 and 100 J/cm2) and high PDT light dose (150 and 200 J/cm2). Complete
response at 3 months was evaluated with a planned biopsy at that timepoint. Kaplan Meier
analysis with log-rank analysis of local recurrence-free survival was used to compare the
low and high PDT light dose groups. For assessment of toxicity between the low and high
dose groups, two-sided Fisher exact test was used to assess for statistical significance
between the two groups.

Results

Author Manuscript

From November 2009 to October 2014, 35 subjects were enrolled. Two of the subjects were
the same patient undergoing separate treatment for a second primary (1 subject) or recurrent
disease (1 subject). One patient who tolerated initial treatment at 50 J/cm2 without
complication was treated for a second time 10 months later for a local recurrence at a higher
dose (150 J/cm2, fractionated). This patient who had history of liver transplant on
immunosuppression underwent treatment and developed expected edema at the treatment
site which quickly resolved but then developed pulmonary edema and sepsis of either
pulmonary or urinary origin, and significant hypoxemia from a tension pneumothorax. It
was determined that the pneumonia, sepsis and respiratory failure could possibly be related
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to study treatment with the patient's immunosuppression as a possible contributing factor.
On autopsy, cause of death in relation to ALA and PDT could not be conclusively
determined.

Author Manuscript
Author Manuscript

Five subjects could not be treated with PDT light after ALA administration, although 2 of
these subjects subsequently underwent successful treatment with ALA-PDT. Since the
events preventing light delivery occurred prior to the administration of the experimental
aspect of this dose escalating protocol for PDT illumination, these patients were not
considered to have experienced a DLT. One patient was found to have an elevated creatinine
level after ALA administration and the procedure was aborted; this event was subsequently
found not to represent artifact of ALA interaction with the Jaffe method for calculating
creatinine instead of true renal failure [21]. This patient subsequently underwent PDT with
ALA successfully. A second patient was found to have developed quick interval progression
when examined in the operating room, making her a poor candidate for light; she underwent
reresection and subsequently received PDT with ALA for high-grade dysplasia at the
surgical margin. A third patient developed laryngeal edema in the operating room,
subsequent to attempts at intubation and prior to delivery of PDT light. The cause of the
edema was uncertain, but may have been related to prolonged light exposure from repeated
attempts at intubation by a new anesthesiology trainee. The patient ultimately opted for
resection. A fourth patient became profoundly hypotensive after administration of anesthetic
in the operating room prior to delivery of PDT light but after the administration of ALA, and
the procedure was aborted. A fifth patient developed transaminitis and became hypotensive
after receiving ALA but prior to undergoing anesthesia, and could not receive PDT. Since
hypotension is a known ALA side effect, especially in patients with cardiovascular
comorbidities, care was taken to avoid enrollment of subjects with significant cardiovascular
comorbidities [22]. Patients were regularly monitored for changes in blood pressure after
administration ALA (every 15 min for 2 h) per protocol. Two patients were initially unable
to undergo PDT illumination due to hypotension. Due to this hypotension effect, it became
our policy to administer intravenous hydration in the 4–6 h between ALA and PDT
administration at a rate of 100 mL per hour.

Author Manuscript

Of the 30 patients who received ALA and illumination, 7 received 50 J/cm2 (3 nonfractionated and 4 fractionated), 6 received 100 J/cm2 (3 non-fractionated and 3
fractionated), 9 received 150 J/cm2 (6 non-fractionated and 3 fractionated), and 8 received
200 J/cm2 (4 non-fractionated and 4 fractionated). One patient in the 150 J/cm2 nonfractionated cohort developed a DLT, thus the protocol required enrollment of 6 patients
under these illumination conditions (5 patients were evaluable due to the death). Therefore, a
total of 29 patients were evaluable (Table 1). The median followup period of evaluable
patients was 41.6 months (range, 3.2–59.4 months).
In patients who underwent the procedure, toxicities were tolerable (Table 2). The most
common toxicity was mucositis, which occurred in 86% of patients treated at 50 J/cm2 and
100% of patients treated at the higher light doses. In all cases, mucositis was grade 3 or
lower in severity, but patients who received higher doses of PDT light (150 and 200 J/cm2)
had higher rates of grade ≥2 mucositis than those who received lower PDT light doses (50
and 100 J/cm2). This difference approached statistical significance (77% versus 100%
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respectively for lower and higher doses, p = 0.078). In all cases, the mucositis resolved by 30
days. No pain was reported by subjects treated with 50 J/cm2, but this increased to 33% of
subjects reporting pain after treatment at 100 J/cm2, with 88% and 63% reporting pain after
treatment at 150 and 200 J/cm2, respectively. Six patients reported grade 1, 7 patients
reported grade 2, and 1 patient who was treated at 150 J/cm2 reported transient grade 3 pain.
More patients who received lower doses of PDT light (50 and 100 J/cm2) reported no or
grade 1 pain compared to patients who received higher doses (150 and 200 J/cm2) of PDT
light (8% versus 44%, p = 0.044). The manifestations of pain and mucositis almost
universally resolved by the week 2 visit, with no pain or mucositis events representing a
DLT.

Author Manuscript

Tongue swelling occurred in 14%, 17%, 38%, and 25% of patients treated at 50, 100, 150,
and 200 J/cm2 respectively, which were all grade 2 or less and quickly resolved. Treatment
resulted in one instance of grade 4 odynophagia and one instance of grade 3 voice alteration
at a light dose of 50 J/cm2; another six cases of transient odynophagia or voice alteration
that were all grade 1 or grade 2 occurred at higher light doses. Weight loss was minimal and
no different between treatment groups, with one grade 1 and two grade 2 episodes of weight
loss. Photosensitivity reactions of grade 2 or less occurred in 10 of 29 evaluable patients who
received ALA and light. Rates of grade 2 or higher aspiration, infection, liver toxicities, and
neuropathy were also not different among the light doses. We could not detect a difference in
toxicities between the fractionated and continuous-light cohorts.

Author Manuscript

There is not yet enough follow-up to determine long-term dose response. At 3-months,
complete response as determined by biopsy was obtained for 20/29 (69%) of patients. The 3month complete response rate was 5/7 (71%) for the 50 J/cm2 cohort, 3/6 (50%) for the 100
J/cm2 cohort, 6/8 (75%) for the 150 J/cm2 cohort and 6/8 (75%) for the 200 J/cm2 cohort (p
= 0.82). One patient treated in the 100 J/cm2 non-fractionated arm experienced local failure
at 1 month, and 5 months later was retreated in the 200 J/cm2 fractionated arm as primary
retreatment; she has no evidence of disease 41 months after retreatment. There was no
difference in local recurrence between the fractionated and non-fractionated groups (not
shown, p = 0.82).

Author Manuscript

Preliminarily, patterns of local recurrence appear more pronounced in lower dose arms that
progressive decreases with higher PDT doses (Table 3). Local recurrences occurred at rates
of 57%, 33%, 25% and 25% after PDT at 50, 100, 150, and 200 J/cm2, respectively. These
findings are confounded by shorter follow-up for higher-dose arms with the lower light dose
group having a 55 month median follow-up and the higher light dose group having a 30
month median follow-up, with the last 3 enrolled patients having been followed for 6
months. It is worthwhile to note that local recurrences occurred within a median 2.9 months
after PDT administration (range [1.3, 19.0 months]) (Fig. 1). There was a 69% complete
response rate for subjects treated with all fluences. No statistically significant difference was
detected in local recurrence rates between the two low (50 and 100 J/cm2) and two high (150
and 200 J/cm2) light dose groups at this early juncture (p = 0.87). The 6-month local
recurrence-free rate for the 50 and 100 J/cm2 cohort was 59%, while the rate for the 150 and
200 J/cm2 cohort was 66%. In the 24 patients with oral cavity lesions, the 6-month local
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recurrence-free rate for the 50 and 100 J/cm2 cohort was 45%, while the rate for the 150 and
200 J/cm2 cohort was 61%.

Author Manuscript

Of the 29 patients, 7 (24%) underwent progression to invasive disease in the area of or
adjacent to the treated field. This study was notable for the high rate of marginal recurrences,
with rates of 25–63% depending on treatment cohort (Table 3). At 6 months, there was no
difference in marginal recurrence with a marginal recurrence-free survival rate for the 50 and
100 J/cm2 cohorts of 92% (95% confidence interval [54%, 99%]), and a rate for the 150 and
200 J/cm2 cohorts of 55.9% (95% confidence interval [25%, 78%]). Marginal and out-offield recurrences occurred within a median 2.7 months after PDT administration (range [1.2,
27.3 months]). While the 50 J/cm2 group had no marginal recurrences but higher local
failure rates (57% compared to 25–33% for the 100–200 J/cm2 groups, Table 3), many of the
patients in this cohort with local failures were lost to follow-up soon after their local
recurrences and could not be assessed for subsequent marginal recurrence. A treatment field
encompassing an extended area surrounding the visible boundaries of the lesion was used
for treatment of the last 5 subjects. In patients in whom an extended treatment field was not
used, 7/24 patients (29%) experienced a marginal recurrence at 6 months, compared to 0/5
patients who were treated with extended treatment fields.

Discussion

Author Manuscript

In this phase 1 series, we find that treatment of premalignant and early stage head and neck
tumors with PDT is generally well tolerated. We found an expected rate of side effects, with
pain and mucositis dependent on dose of the PDT light used. DLT was not reached in our
cohort of patients. Ultimately, 2 patients could not be treated with ALA-PDT due to an
effect of Levulan precipitating hypotensive episodes and/or transaminitis; this has prompted
us to carefully select patients without significant cardiovascular history prior to offering
PDT with ALA. One patient developed laryngeal edema, but this was consistent with a
reaction to the light used for intubation for general anesthesia after ALA but prior to light
administration. One patient with significant medical comorbidities developed sepsis and
pulmonary edema, passing away in a manner that could possibly be related to his treatment.

Author Manuscript

Whether control at the local site is improved with higher doses of PDT light is uncertain in
this interim analysis, and this study is not powered to make that determination. A
confounding factor in an interim evaluation of efficacy is the mix of patients who received
ALA-PDT definitively for unresected disease (18 patients) or for dysplasia, carcinoma in
situ or microinvasive carcinoma at the margin of resected disease (11 patients), although the
proportions of definitive versus adjuvant treatment was generally balanced amongst the PDT
doses (Table 1). However, patients with moderate and high grade dysplasias present at the
surgical margin in oral cavity cancers have been demonstrated to have a 51% rate of local
recurrence [23], similar to progression rates expected for unresected high-grade dysplasias.
We also found a significant rate of marginal recurrences when the local site is controlled. As
we appreciated this phenomenon, we widened the PDT light field to account for field
precancerization amid concerns that we were generally underestimating the area at risk for
recurrence. Indeed, other studies have shown that areas previously thought to be tumor-free
have precursor lesions with genetic changes predisposing for local or marginal recurrences
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[24]. Among the 5 patients who were treated with the larger fields, there have been no cases
of marginal recurrence.

Author Manuscript

Several reports indicate that patients with early stage cancer or early recurrences in the head
and neck, particularly the oral cavity and larynx, have excellent responses to PDT [25,26].
Biel et al. treated 48 patients with early head and neck squamous cell carcinomas using the
photosensitizer Photofrin. Of those, 25 had carcinoma in situ (CIS) and T1 cancers, 17 of
which were radiation therapy failures. There was a complete clinical and pathologic
response in all patients and they remained without recurrence at a mean follow-up of 27
months. An additional 23 patients had early carcinomas (CIS, T1 and T2) of the oral cavity,
nasal cavity and nasopharynx. After treatment, all patients achieved a complete response rate
of 87% [27]. In a review of the literature, Biel noted a complete response rate of 85%
(145/171) after a single PDT treatment with Photofrin in patients with CIS, T1 and T2
cancers of the oral cavity, larynx, and pharynx [28].
ALA has previously been used for head and neck lesions. Four patients were treated with
ALA for head and neck squamous cell carcinoma, and the treatment was found to be
tolerable [29]. Fan et al. used ALA with fractionated (two-part) light delivery to 100 or 200
J/cm2 for 18 patients with moderate and high-grade dysplasia as well as invasive carcinoma
of the head and neck. Of the 5 patients treated with high-grade dysplasia, there was a
complete pathological response in 3 out of 4 evaluable patients. One out of 6 patients with
invasive disease had complete pathologic response. This was felt to be due to limited depth
of penetration of thick invasive lesions. There were no reports of issues with hypotension or
permanent episodes of liver dysfunction in these series [30].

Author Manuscript

We find PDT with ALA to be safe with generally tolerable side effects in our population of
patients with high-grade dysplasia, carcinoma in situ, and early stage carcinomas of the head
and neck. DLT was not reached in our study, and we would recommend that PDT-ALA be
advanced to a phase II trial to determine efficacy, at our highest light dose of 200 J/cm2.

Conclusions

Author Manuscript

We find that administration of photodynamic therapy with Levulan allows for shortened
periods of light restriction, and is generally well tolerated. We find suggestion that the
regimen is effective in terms of local control especially at higher light doses, when the
alternative involves function-altering resection. There was an initially high rate of marginal
recurrences, and larger treatment fields should be considered. More followup is required to
estimate local control, especially when comparing the effectiveness of lower versus higher
PDT light doses.
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Fig. 1.

Local recurrence-free survival for all patients (n = 29).
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Table 1

Author Manuscript

Patient characteristics.
Total

50 J/cm2

100 J/cm2

150 J/cm2

200 J/cm2

Total

(number)

29

7

6

8

8

Age

(Median, years)

62

70

57

56

64

Gender (no.)

Male

10

3

3

2

2

Female

19

4

3

6

6

Tongue/floor of mouth

Primary site

Author Manuscript

Intact versus post-op

Initial versus recurrent

Invasiveness

18

6

3

5

4

Buccal

4

0

1

1

2

Alveolar ridge

1

0

0

0

1

Lower lip

1

0

0

0

1

Glottic larynx

4

1

2

1

0

Nasal cavity

1

0

0

1

0

Intact (definitive)

18

6

4

4

4

Postoperative (involved margins)

11

1

2

4

4

Initial

11

2

3

4

2

Recurrent

18

5

3

4

6

High-grade dysplasia

18

3

5

3

7

Carcinoma in-situ

8

4

0

3

1

Invasive carcinoma

3

0

1

2

0

Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript
0
2 (29%)
1 (14%)
1 (14%)
5 (71%)

Photo-sensitivity

Tongue swelling

Voice alterations

Abnormal liver function

Grade 1 to 4 included.

a

1 (14%)

Weight loss

6 (86%)

Odynophagia

0

Mucositis

0

1 (14%)

0

0

0

0

3 (43%)

0

0

0

0

0

0

1 (14%)

0

0

Grade
4 # (%)

4 (67%)

3 (50%)

1 (17%)

3 (50%)

0

2 (33%)

6 (100%)

2 (33%)

All
Grades #
(%)

1 (17%)

0

0

0

0

0

2 (33%)

0

Grade
3 # (%)

a

Grade
3 # (%)

a
All
Grades
# (%)

100 J/cm2 (N = 6)

50 J/cm2 (N = 7)

Pain

Toxicity

0

0

0

0

0

0

0

0

Grade
4#
(%)

5 (63%)

1 (13%)

3 (38%)

3 (38%)

1 (13%)

2 (25%)

8 (100%)

7 (88%)

All
Grades #
(%)

a

0

0

0

0

0

0

6 (75%)

1 (13%)

Grade
3 # (%)

150 J/cm2 (N = 8)

0

0

0

0

0

0

0

0

Grade
4#
(%)

3 (38%)

2 (25%)

2 (25%)

2 (25%)

2 (25%)

2 (25%)

8 (100%)

5 (63%)

All
Grades #
(%)

a

1 (13%)

0

0

0

0

0

4 (50%)

0

Grade
3 # (%)

200 J/cm2 (N = 8)

0

0

0

0

0

0

0

0

Grade
4#
(%)

17 (59%)

7 (24%)

7 (24%)

10 (34%)

3 (10%)

7 (24%)

28 (97%)

14 (48%)

All
Grades #
(%)

a

1 (3%)

1 (3%)

0

0

0

0

15 (52%)

1 (3%)

Grade 3
# (%)

0

0

0

0

0

1 (3%)

0

0

Grade
4#
(%)

All patients treated (N = 29)

Toxicities as a function of PDT light dose for patients treated with continuous (unfractionated) and fractionated (two-part) illumination.
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Table 3

Author Manuscript

Recurrence rates as a function of PDT light dose and continuous (unfractionated) versus fractionated (twopart) illumination. Recurrences are separated into those that are local and those that are marginal.
Dose

Fractionated

Total number

Local recurrence (%)

Marginal recurrence (%)

7

4 (57%)

0

No

3

2 (67%)

0

Yes

4

2 (50%)

0

50 Combined

100 Combined

6

2 (33%)

3 (50%)

No

3

1 (33%)

2 (67%)

Yes

3

1 (33%)

1 (33%)

8

2 (25%)

5 (63%)

No

5

1 (20%)

3 (60%)

Yes

3

1 (33%)

2 (67%)

150 Combined

Author Manuscript

200 Combined

8

2 (25%)

2 (25%)

No

4

1 (25%)

0

Yes

4

1 (25%)

2 (50%)
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